Our top pick for
Luminex Corporation is a medical instruments & supplies business based in the US. Luminex Corporation shares (LMNX) are listed on the NASDAQ and all prices are listed in US Dollars. Luminex Corporation employs 1,325 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$20.47 - $41.25|
|50-day moving average||$34.06|
|200-day moving average||$27.66|
|Wall St. target price||$34.50|
|Dividend yield||$0.37 (1.01%)|
|Earnings per share (TTM)||$0.33|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Luminex Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Luminex Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Luminex Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 113x. In other words, Luminex Corporation shares trade at around 113x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Luminex Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.7. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Luminex Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Luminex Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $72.9 million.
The EBITDA is a measure of a Luminex Corporation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$417.4 million|
|Operating margin TTM||10.17%|
|Gross profit TTM||$247.9 million|
|Return on assets TTM||3.88%|
|Return on equity TTM||3.09%|
|Market capitalisation||$1.7 billion|
TTM: trailing 12 months
There are currently 2.4 million Luminex Corporation shares held short by investors – that's known as Luminex Corporation's "short interest". This figure is 22% down from 3.1 million last month.
There are a few different ways that this level of interest in shorting Luminex Corporation shares can be evaluated.
Luminex Corporation's "short interest ratio" (SIR) is the quantity of Luminex Corporation shares currently shorted divided by the average quantity of Luminex Corporation shares traded daily (recently around 1.6 million). Luminex Corporation's SIR currently stands at 1.51. In other words for every 100,000 Luminex Corporation shares traded daily on the market, roughly 1510 shares are currently held short.
However Luminex Corporation's short interest can also be evaluated against the total number of Luminex Corporation shares, or, against the total number of tradable Luminex Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Luminex Corporation's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Luminex Corporation shares in existence, roughly 50 shares are currently held short) or 0.0726% of the tradable shares (for every 100,000 tradable Luminex Corporation shares, roughly 73 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Luminex Corporation.
Find out more about how you can short Luminex Corporation stock.
Dividend payout ratio: 1.15% of net profits
Recently Luminex Corporation has paid out, on average, around 1.15% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.09% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Luminex Corporation shareholders could enjoy a 1.09% return on their shares, in the form of dividend payments. In Luminex Corporation's case, that would currently equate to about $0.37 per share.
While Luminex Corporation's payout ratio might seem low, this can signify that Luminex Corporation is investing more in its future growth.
Luminex Corporation's most recent dividend payout was on 14 April 2021. The latest dividend was paid out to all shareholders who bought their shares by 23 March 2021 (the "ex-dividend date").
Over the last 12 months, Luminex Corporation's shares have ranged in value from as little as $20.4655 up to $41.2466. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Luminex Corporation's is 0.5339. This would suggest that Luminex Corporation's shares are less volatile than average (for this exchange).
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; and TDAS, an analysis program designed for development and optimization of nucleic acid assays. The company also provides xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism; ARIES system, a sample to answer real-time PCR platform; SYNCT data management software solutions; and ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 Assay, ARIES Flu A/B & RSV Assay, ARIES Group B Streptococcus Assay, ARIES Group A Strep Assay, ARIES Bordetella Assay, ARIES Norovirus Assay, ARIES C. difficile Assay, ARIES MRSA Assay, and SARS-CoV-2 Assay. In addition, it offers VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; VERIGENE test cartridges; Amnis FlowSight imaging flow cytometers; Amnis ImageStream Mark II imaging flow cytometers; Amnis CellStream for cell and particle analysis; Guava easyCyte benchtop flow cytometers; Muse cell analyzers; and IDEAS, an image analysis software. Luminex Corporation was founded in 1995 and is based in Austin, Texas. .
Everything we know about the Krispy Kreme IPO, plus information on how to buy in.
Everything we know about the Day One Biopharmaceuticals IPO, plus information on how to buy in.
Everything we know about the Enact Holdings IPO, plus information on how to buy in.
Everything we know about the Solid Power IPO, plus information on how to buy in.
Everything we know about the Paymentus Holdings IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Ximalaya IPO, plus information on how to buy in.
Everything we know about the Zeta Global Holdings Corp IPO, plus information on how to buy in.
Everything we know about the Paycor HCM IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.